Indivior is a specialty pharmaceutical company focused on treatments for opioid use disorder and related addiction medicine. Its portfolio has long centered on buprenorphine-based therapies (including well-known brands in film and other formulations) used in medication-assisted treatment. The company markets primarily to healthcare providers, treatment clinics and health systems involved in substance-use care. Differentiation rests on clinical focus in addiction rather than a broad primary-care drug franchise.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 302 | — | 18 | — |
| Q3 2025 | 314 | — | 42 | — |
| Q4 2025 | 358 | — | 102 | — |
| Q1 2026 | 317 | — | 89 | — |
| Q2 2026 | 343 | 13.6% | 122 | 577.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: AbCellera Biologics Inc. (ABCL), monday.com Ltd. (MNDY), Diodes Incorporated (DIOD), Otter Tail Corporation (OTTR), Independent Bank Corp. (INDB), Cipher Digital Inc. (CIFR)